CARDIOKINE INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Active:0

Completed:6

Trial Phases

3 Phases

Phase 1:1

Phase 2:1

Phase 3:4

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 3

4 (66.7%)

Phase 1

1 (16.7%)

Phase 2

1 (16.7%)

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

Completed

Conditions: Hyponatremia With Normal Extracellular Fluid Volume
Hyponatremia With Excess Extracellular Fluid Volume

First Posted Date: 2010-01-26

Last Posted Date: 2011-06-21

Lead Sponsor: CardioKine Inc.

Target Recruit Count: 135

Registration Number: NCT01056848

Locations: 🇺🇸
Torrance Clinical Research, Lomita, California, United States
🇺🇸
Innovative Research of West Florida, Clearewater, Florida, United States
🇺🇸
Fleming Island Center for Clinical Research, Fleming Island, Florida, United States

and more 3 locations

Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Phase 2

Completed

Conditions: Congestive Heart Failure

Interventions: Drug: Placebo
Drug: Lixivaptan

First Posted Date: 2010-01-26

Last Posted Date: 2011-06-28

Lead Sponsor: CardioKine Inc.

Target Recruit Count: 170

Registration Number: NCT01055912

Locations: 🇺🇸
Mobile Heart Specialists, PC, Mobile, Alabama, United States
🇺🇸
Phoenix Clinical, Phoenix, Arizona, United States
🇺🇸
Nea Clinic, Jonesboro, Arkansas, United States

and more 22 locations

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Phase 3

Completed

Conditions: Euvolemic Hyponatremia

Interventions: Drug: Placebo
Drug: Lixivaptan

First Posted Date: 2009-04-07

Last Posted Date: 2011-06-28

Lead Sponsor: CardioKine Inc.

Target Recruit Count: 206

Registration Number: NCT00876798

Locations: 🇺🇸
Birmingham Nursing and Rehabilitation East, Birmingham, Alabama, United States
🇺🇸
Healthscan Research, LLC, Montgomery, Alabama, United States
🇺🇸
PsyPharma Clinical Research, Inc., Phoenix, Arizona, United States

and more 86 locations